Skip Navigation

JNCI Journal of the National Cancer Institute 2003 95(4):254-255; doi:10.1093/jnci/95.4.254
© 2003 by Oxford University Press
This Article
Right arrow Full Text Freely available
Right arrow Correction (v95,p510)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Request Permissions
Google Scholar
Right arrow Articles by Tuma, R. S.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Tuma, R. S.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Journal of the National Cancer Institute, Vol. 95, No. 4, 254-255, February 19, 2003
© 2003 Oxford University Press

NEWS

Dosing Study Seen As Victory for Clinical Trials, Mathematical Models

Rabiya S. Tuma

The first 10% of the full text of this article appears below.

A recent Cancer and Leukemia Group B (CALGB) clinical trial was by all accounts a major success; by simply decreasing the interval between chemotherapy treatments from 3 weeks to 2 weeks, clinicians saw a 26% proportional improvement in disease-free survival and a 31% proportional improvement in overall survival in women with node-positive breast cancer following surgery.

But for many researchers the importance of the trial goes beyond finding an improved method of treatment. It is also a proof of concept, of the Norton-Simon Regression model specifically, and . . . [Full Text of this Article]

Trial Design and Results

Mathematical Models


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 Cancer Res.Home page
A. A. Kamat, T. J. Kim, C. N. Landen Jr., C. Lu, L. Y. Han, Y. G. Lin, W. M. Merritt, P. H. Thaker, D. M. Gershenson, F. Z. Bischoff, et al.
Metronomic Chemotherapy Enhances the Efficacy of Antivascular Therapy in Ovarian Cancer
Cancer Res., January 1, 2007; 67(1): 281 - 288.
[Abstract] [Full Text] [PDF]